AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
PR Newswire•03/11/2026•16:01 ET
0
Key Highlights
- ➤Q3 revenue $10.4 billion, up 8% year-over-year
- ➤GAAP EPS $7.08, up 19% year-over-year
- ➤2026 revenue guidance set at $38.9 billion to $39.7 billion
- ➤UPLIZNA sales $451 million, up 191% year-over-year
- ➤Prolia sales $632 million, down 45% as biosimilars launched globally
Expert Statements
Robert A. Bradway, Chairman and Chief Executive Officer of Amgen
“Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise.”
Robert A. Bradway, Chairman and Chief Executive Officer of Amgen
“The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen's ability to deliver durable growth well into the next decade.”
AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS PR Newswire
THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.
Get started
Create a free account to read the full story.